Healthcare Industry News: excimer laser
News Release - June 25, 2009
Spectranetics Names Jason Hein Senior VP, Sales, Marketing and Product Development
Appointment Consolidates Leadership of Vascular Intervention and Lead Management BusinessesCOLORADO SPRINGS, Colo.--(HSMN NewsFeed)--Spectranetics Corporation (Nasdaq:SPNC ) today announced the appointment of Jason Hein to the position of Senior Vice President, Sales, Marketing and Product Development for both the Vascular Intervention and Lead Management businesses. Also, Renee Boehme, Director, Lead Management Sales has been promoted to Vice President, U.S. Sales -- Lead Management.
Spectranetics Chairman, President and Chief Executive Officer Emile Geisenheimer commented, “The promotion of Jason into his new role consolidates the leadership of our Vascular Intervention and Lead Management businesses, allowing us to streamline decision making and enhance operating efficiencies as we continue our drive towards profitability. I continue to be excited about the revenue growth prospects in both the Vascular Intervention and Lead Management businesses, which growth is driven by the strength of their respective highly capable field sales organizations.
“Since joining Spectranetics in July 2006, Jason has implemented several significant initiatives in the Lead Management business, including the creation of a separate sales organization, implementation and successful conclusion of the LExICon retrospective study supporting positive clinical outcomes utilizing laser-assisted lead extraction, and an impressive showcase of Spectranetics lead management products at the recently concluded Heart Rhythm Society meeting, where the guidelines for lead extraction were expanded. He has built an exceptional management team and has proven himself to be a strong leader, resulting in the rapid rate of growth in our Lead Management business. I look forward to working with Jason in his expanded role,” said Geisenheimer.
Mr. Geisenheimer concluded, “This reorganization eliminates the position of Vice President, General Manager, Vascular Intervention.”
About Spectranetics
Spectranetics manufactures and markets the only excimer laser System approved in the United States, Canada, Europe and Japan for use in minimally invasive interventional procedures within the cardiovascular system. More than 800 Spectranetics laser systems are used in hospitals worldwide.
The Company’s Vascular Intervention (VI) products include a range of peripheral and cardiac laser catheters for ablation of occluded arteries above and below the knee and within coronary arteries. The Company also markets aspiration catheters for the removal of thrombus and support catheters to facilitate crossing of coronary and peripheral arterial blockages.
The Lead Management (LM) product line includes excimer laser sheaths and cardiac lead management accessories for the removal of pacemaker and defibrillator cardiac leads. For more information visit www.spectranetics.com.
Safe Harbor Statement
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties may include adverse results of the FDA and Immigration and Customs Enforcement investigation, adverse results of the SEC investigation or any securities litigation in which the Company or any of its officers or directors is a party, market acceptance of excimer laser atherectomy technology, increasing price and product competition, increased pressure on expense levels resulting from expanded sales, marketing, product development and clinical activities, uncertain success of the Company's strategic direction, dependence on new product development, intellectual property claims of third parties, availability of inventory from suppliers, the receipt of FDA approval to market new products or applications and the timeliness of any approvals, market acceptance of new products or applications, product defects, ability to manufacture sufficient volumes to fulfill customer demand, availability of vendor-sourced components at reasonable prices, unexpected delays or costs associated with the Company’s relocation and consolidation of its headquarters and manufacturing operations, and price volatility due to the initiation or cessation of coverage, or changes in ratings, by securities analysts. For a further list and description of such risks and uncertainties that could cause the actual results, performance or achievements of the Company to be materially different from any anticipated results, performance or achievements, please see the Company's previously filed SEC reports. Spectranetics disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether as a result of new information, future events or otherwise.
Source: Spectranetics
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
